RxDoctor Payments Data

Chunyang Wang, MD

Neurology · Escondido, CANPI 1386890770

Payments from drug & device makers

$36,214in general payments, 2019–2025

Across 813 payments — averaging $44.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$20K
  • UCB, Inc.$4K
  • AbbVie$2K
  • Sunovion Pharmaceuticals Inc.$1K
  • SK Life Science, Inc.$1K
  • Neurelis, Inc.$1K
  • plus $7K from 53 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$15,90099%
  • Education$1261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA4$20,164
UCB, Inc.135$3,503
AbbVie(2 entities)82$1,507
Sunovion Pharmaceuticals Inc.104$1,441
SK Life Science, Inc.62$1,121
Neurelis, Inc.63$1,085
Lilly USA, LLC46$897
Lundbeck LLC32$582
Eisai Inc.19$412
Supernus Pharmaceuticals, Inc.26$401
Jazz Pharmaceuticals Inc.6$314
Amgen17$313
Sumitomo Pharma America, Inc.16$302
Medtronic(3 entities)5$277
Acadia Pharmaceuticals Inc8$277
Livanova USA, Inc.16$269
Greenwich Biosciences, Inc.9$260
Teva Pharmaceuticals USA, Inc.18$259
Neurocrine Biosciences, Inc.10$250
Avanir Pharmaceuticals, Inc.19$226
Alnylam Pharmaceuticals Inc.10$195
AstraZeneca(2 entities)5$161
Novartis9$151
Biohaven Pharmaceuticals, Inc.8$129
Aquestive Therapeutics, Inc.6$129
Pfizer7$111
Biogen6$110
Corcept Therapeutics1$104
Upsher-smith Laboratories LLC6$104
Kyowa Kirin, Inc.4$93
Otsuka America Pharmaceutical, Inc.4$83
Philips North America LLC2$77
EMD Serono, Inc.4$77
Catalyst Pharmaceuticals, Inc.3$67
Arbor Pharmaceuticals, Inc.4$62
Sanofi3$60
Almatica Pharma LLC3$55
Tanabe Pharma America, Inc.2$54
Vertical Pharmaceuticals, LLC3$49
Zogenix Inc.2$48
Corium, LLC2$47
Neuropace, Inc.2$38
Johnson & Johnson1$33
Grifols USA, LLC2$30
Argenx US, Inc.1$30
Axsome Therapeutics, Inc.1$29
Acorda Therapeutics, Inc1$24
MDD US Operations, LLC1$23
Impel Pharmaceuticals LLC1$22
Amneal Pharmaceuticals LLC1$21
Biohaven Pharmaceutical Holding Company Ltd.1$20
Tonix Medicines, Inc.1$20
Itamar Medical Inc1$20
Abbott1$19
Impel Pharmaceuticals Inc.1$19
Azurity Pharmaceuticals, Inc.1$15
Assertio Therapeutics, Inc.1$14
Zyla Life Sciences, Inc.1$11
Travere Therapeutics, Inc.3$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,214 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$169,707
Medicare patients
347
Services billed
4,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate87$198,570
EpidiolexCannabidiol (Cbd)25$101,515
Topiramate ErTopiramate87$89,083
BriviactBrivaracetam54$80,672
OnfiClobazam16$49,265
XcopriCenobamate19$35,327
Lamictal XrLamotrigine13$24,353
KeppraLevetiracetam19$23,979
Trokendi XrTopiramate16$16,626
Lacosamide143$16,215
ValtocoDiazepam11$13,849
Lamotrigine ErLamotrigine61$13,053
NayzilamMidazolam11$12,601
Memantine Hcl46$6,382
Levetiracetam197$6,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$1,441$198,57087 claims
UCB, Inc.Briviact, Nayzilam$3,503$93,27365 claims
Lundbeck LLCOnfi$582$49,26516 claims
SK Life Science, Inc.Xcopri$1,121$35,32719 claims
UCB SAKeppra$20,164$23,97919 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$401$16,62616 claims
Neurelis, Inc.Valtoco$1,085$13,84911 claims
Upsher-smith Laboratories LLCTopiramate$104$53143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Escondido

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →